Home

The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.

This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:

MaRS Discovery District 
101 College Street, 
Toronto, ON  
M5G 1L7

 

Confirmed speakers include:

Marco Marra, PhD, BC Cancer Agency

Anthony Letai, MD, PhD, Dana-Farber Cancer Institute

Nadeem Riaz, MD, Memorial Sloan Kettering Cancer Center

Daniel De Carvalho, PhD, Princess Margaret Cancer Centre 

Padmanee Sharma, MD, PhD, MD Anderson Cancer Center

Stephen Schuster, MD, Hospital of the University of Pennsylvania

Charles Drake, MD, PhD, Herbert Irving Comprehensive Cancer Center

Bryan Coburn, MD, PhD, Toronto General Hospital

 

Target Audience for the 2018 Cancer Genomics and Tumor Immunotherapy Symposium:

  • Oncologists: Medical, Radiation, Surgical
  • Pathologists
  • Clinical Geneticists
  • Genetic Counselors
  • Laboratory Directors
  • Laboratory Technicians
  • Oncology Nurses
  • Bioinformaticians
  • Basic and Translational Scientists
  • Basic, Translational and Clinical Trainees
  • Pharmaceutical Representatives

 

Topics to be discussed in a presentation or panel include:

  • Personalized Oncogenomics (POG)
  • Augmenting Genomics with Functional Precision Medicine in Cancer
  • The Cancer Genome's Influence on Immunotherapy
  • Epigenetics and Circulating DNA
  • Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
  • CAR-T Therapy
  • Personalized Cancer Vaccines
  • The Intestinal Microbiota and Immunotherapy Responsiveness